

BAB IV

DAFTAR PUSTAKA

- Beham-Schmid, C. 2017. Aggressive lymphoma 2016: revision of the WHO classification. *Memo*, 10(4), 248–254. DOI:10.1007/s12254-017-0367-8
- Bray, F. *et al.* 2018. Global cancer statistics 2018: Globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA: A Cancer Journal for Clinicians*, 68(6), pp. 394–424. DOI:10.3322/caac.21492
- canreg.fkkmk, O. 2022. *RKBR Maret 2022, Universitas Gadjah Mada*. Available at: <https://canreg.fk.ugm.ac.id/laporan-data/registrasi-kanker-berbasis-rumah-sakit-dr-sardjito-fkkmk-ugm/rkbr-maret-2022/> (Accessed: 2 September 2023).
- Carbone, A., Gloghini, A., & Dotti, G. 2008. EBV-associated lymphoproliferative disorders: Classification and treatment. *The Oncologist*, 13(5), 577–585. <https://doi.org/10.1634/theoncologist.2008-0036>
- Chiu, B. C., & Weisenburger, D. D. 2003. An update of the epidemiology of non-Hodgkin's lymphoma. *Clinical lymphoma*, 4(3), 161–168. DOI:10.3816/clm.2003.n.025
- Coiffier B, Lepage E, Briere J, et al. 2002. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. *N Engl J Med*.;346:235-242
- Costas, *et al.*, 2012 Reproductive factors and lymphoid neoplasms in Europe: findings from the EpiLymph case-control study. *Cancer Causes Control*.;23(1):195-206
- Data dan Kondisi Limfoma di Indonesia*. 2015. *Kementerian Kesehatan Republik Indonesia*. Available at: <https://www.kemkes.go.id/article/view/16010500001/data-dan-kondisi-limfoma-di-indonesia.html> (Accessed: October 28, 2022).
- de Leval, L. and Jaffe, E.S. 2020. Lymphoma classification. *The Cancer Journal*, 26(3), pp. 176–185, DOI:10.1097/ppo.0000000000000451

- Engelhard, *et al.* 1997. Subclassification of Diffuse Large B-Cell Lymphomas According to the Kiel Classification: Distinction of Centroblastic and Immunoblastic Lymphomas Is a Significant Prognostic Risk Factor. *Blood*, 89(7), pp. 2291-2297
- Horn, H., Staiger, A.M., & Vohringer, M., *et al.* 2015. Diffuse large B-cell lymphomas of immunoblastic type are a major reservoir for MYC-IGH translocations. *Am J Surg Pathol*;39:61-6
- HUANG, H.O.N.G.-H.U.I. *et al.* 2012. Reassessment of the prognostic value of the international prognostic index and the Revised International Prognostic Index in patients with diffuse large B-cell lymphoma: A multicentre study. *Experimental and Therapeutic Medicine*, 4(3), pp. 475–480. DOI:10.3892/etm.2012.607
- Jamil, A. and Mukkamalla, S.K.R. 2022. *Lymphoma, StatPearls*. StatPearls Publishing. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/32809661>
- Janssen-Heijnen, M.L.G. *et al.* 2005. A population-based study of severity of comorbidity among patients with non-Hodgkin's lymphoma: Prognostic impact independent of international prognostic index. *British Journal of Haematology*, 129(5), pp. 597–606. doi:10.1111/j.1365-2141.2005.05508.x.
- Kwak J. Y. 2012. Treatment of diffuse large B-cell lymphoma. *The Korean journal of internal medicine*, 27(4), 369–377. DOI:10.3904/kjim.2012.27.4.369
- Li, S., Young, K.H. and Medeiros, L.J. 2018. Diffuse large B-cell lymphoma. *Pathology*, 50(1), pp. 74–87. DOI:10.1016/j.pathol.2017.09.006.
- Lin, T.Y., *et al.* 2005. Comparison between R-CHOP regimen and CHOP regimen in treating naive diffuse large B-cell lymphoma in China--a multi-center randomized trail. *Ai Zheng*. 24(12):1421-6. Chinese. PMID: 16351785.
- Linderöth, J. 2007. Diffuse large B-cell lymphoma - tumour characteristics on RNA and protein level associated with prognosis. *Doctoral Thesis (compilation), Breastcancer-genetics*. Department of Oncology, Clinical Sciences, Lund University.
- López-Guillermo, A. *et al.* 2005. Diffuse large B-cell lymphoma: Clinical and biological characterization and outcome according to the nodal or extranodal primary origin. *Journal of Clinical Oncology*, 23(12), pp. 2797–2804. DOI:10.1200/jco.2005.07.155

- Ma, S. *et al.* 2021. A prognostic immune risk score for diffuse large b-cell lymphoma. *British Journal of Haematology*, 194(1), pp. 111–119. doi:10.1111/bjh.17478.
- Martelli, M. *et al.* 2013. Diffuse large B-cell lymphoma. *Critical Reviews in Oncology/Hematology*, 87(2), pp. 146–171. DOI:10.1016/j.critrevonc.2012.12.009
- Qin, Y. *et al.* 2020. Characteristics and Management of TP53-mutated diffuse large B-cell lymphoma patients. *Cancer Management and Research*, Volume 12, pp. 11515–11522. doi:10.2147/cmar.s269624.
- Ruppert, A.S. *et al.* 2020. ‘International prognostic indices in diffuse large B-cell lymphoma: A comparison of IPI, R-IPI, and NCCN-IPI’, *Blood*, 135(23), pp. 2041–2048. doi:10.1182/blood.2019002729.
- Rovira, J. *et al.* 2014. Prognosis of patients with diffuse large B-cell lymphoma not reaching complete response or relapsing after frontline chemotherapy or immunochemotherapy. *Annals of Hematology*, 94(5), pp. 803–812, DOI:10.1007/s00277-014-2271-1
- Salar, A., Fernández de Sevilla, A., Romagosa, V., Domingo-Claros, A., González-Barca, E., Pera, J., Climent, J., Grañena, A., 1998. Diffuse large B-cell lymphoma: is morphologic subdivision useful in clinical management? *Eur J Haematol.* 60(3):202-8.
- Sarkozy, C. and Coiffier, B. 2013. Diffuse large B-cell lymphoma in the elderly: A review of potential difficulties. *Clinical Cancer Research*, 19(7), pp. 1660–1669. doi:10.1158/1078-0432.ccr-12-2837.
- Sastroasmoro, S., Ismail, S. 2014. *Dasar-dasar Metodologi Penelitian Klinis*. 5th ed. Jakarta: CV. Sagung Seto, pp. 368 - 76.
- Sehn, L., *et al.* 2007. The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. *Blood*, 109(5), 1857–1861. DOI:10.1182/blood-2006-08-038257
- Shipp, M.A., *et al.* 1993. A Predictive Model for Aggressive Non-Hodgkin’s Lymphoma. The International Non-Hodgkin’s Lymphoma Prognostic Factors Project. *N Engl J Med.* 329:987.

- Swerdlow, S.H., Campo, E., Harris, N.L., Jaffe, E.S., Pileri, S.A., Stein, H., & Thiele, J. 2017. *WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues*. Revised 4th edition. IARC: Lyon
- Swerdlow, SH., 2013. Lymphoma classification and the tools of our trade: an introduction to the 2012 USCAP Long Course. *Mod. Pathol* 26 : S1–S14
- Tai, W., Tang, P., Koo, Y., Hou, X., Tay, K., Quek, R., Tao, M., & Lim, S. (2011). Do we have the right prognostic index for diffuse large B-cell lymphoma (DLBCL) in the era of Rituximab? *Proceedings of Singapore Healthcare*, 20(1), 48–54. <https://doi.org/10.1177/201010581102000108>
- Trajkova, S. *et al.* 2013. Immunoblastic morphology as a possible prognostic indicator for the outcome of the patients with diffuse large B-cell lymphoma in ERA of the Rituximab based treatment: Single Centre experience. *International Journal of Research in Medical Sciences*, 1(2), p. 1. doi:10.5455/2320-6012.ijrms20130501.
- Wang, *et al.* 2018. Prognostic Value of Morphology and Hans Classification in Diffuse Large B-cell Lymphoma. *Zhongguo shi yan xue ye xue za zhi*, 26, pp. 1079-1085, DOI:10.7534/j.issn.1009-2137.2018.04.023